Brokerages expect Minerva Neurosciences Inc (NASDAQ:NERV) to announce earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Minerva Neurosciences’ earnings, with estimates ranging from ($0.47) to ($0.30). Minerva Neurosciences reported earnings per share of ($0.31) in the same quarter last year, which would indicate a negative year over year growth rate of 25.8%. The business is expected to report its next quarterly earnings results on Monday, November 4th.
On average, analysts expect that Minerva Neurosciences will report full year earnings of ($1.50) per share for the current financial year, with EPS estimates ranging from ($1.68) to ($1.33). For the next fiscal year, analysts expect that the business will post earnings of ($2.53) per share, with EPS estimates ranging from ($3.31) to ($1.74). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Minerva Neurosciences.
Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.10.
In related news, major shareholder Venture Associates L. Index III sold 110,818 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $4.41, for a total transaction of $488,707.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David Kupfer purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 26th. The shares were purchased at an average cost of $5.55 per share, for a total transaction of $55,500.00. Following the completion of the transaction, the director now owns 219,188 shares in the company, valued at approximately $1,216,493.40. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 413,736 shares of company stock worth $2,142,953. Corporate insiders own 12.00% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. TD Asset Management Inc. grew its position in shares of Minerva Neurosciences by 2.8% in the 2nd quarter. TD Asset Management Inc. now owns 58,847 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 1,600 shares during the last quarter. Bank of America Corp DE grew its position in shares of Minerva Neurosciences by 17.0% in the 4th quarter. Bank of America Corp DE now owns 20,412 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 2,963 shares during the last quarter. Alps Advisors Inc. grew its position in shares of Minerva Neurosciences by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 93,888 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 4,064 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Minerva Neurosciences by 63,940.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,404 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 6,394 shares during the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Minerva Neurosciences in the 2nd quarter worth approximately $54,000. 74.24% of the stock is currently owned by institutional investors and hedge funds.
Shares of NERV traded down $0.07 during trading on Friday, reaching $8.00. The company’s stock had a trading volume of 134,285 shares, compared to its average volume of 376,813. The company has a fifty day moving average of $6.89 and a two-hundred day moving average of $6.76. Minerva Neurosciences has a twelve month low of $4.07 and a twelve month high of $12.95. The company has a market cap of $312.20 million, a price-to-earnings ratio of -6.20 and a beta of 1.54.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Further Reading: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.